A recent study from the Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California, USA; Center for Liver, Departments of Pediatrics and Laboratory Medicine, University of Groningen, University Medical Center Groningen, The Netherlands; Department of Biochemistry-Molecular Pharmacology, New York University School of Medicine, New York, New York, USA; Department of Medicine, Division of Endocrinology and Metabolism, University of California at San Diego, La Jolla, California, USA; School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, China; and The Storr Liver Unit, Westmead Millennium Institute and University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia shows that “Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer.”
This study was published in the September, 18 2014 issue of Nature (The number 1 journal in Science with an IF of ~42) by Prof. Ronald M. Evans, Jae Myoung Suh, and others from Salk Institute for Biological Studies, La Jolla, California, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Small RNA-based “Insulin sensitizing therapy” for DM: AntagomiR-195 functions as an “insulin sensitizer” via up regulation of its target gene. This study suggests, for the first time, that MiRNA-195, by down regulating its target gene, it may promote insulin sensitivity. Together, this study suggests that pharmacological formulations encompassing “AntagomiR-195 or small molecule compounds that inhibit the expression of miRNA-195” may be used to treat patients suffering from DM. One advantage of this Small RNA-based “Insulin sensitizing therapy, against the currently available treatment, is that a single dose may be sufficient to turn insulin-resistant tissues into insulin-sensitive ones.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Small RNA-based “Insulin sensitizing therapy” for DM: AntagomiR-195 functions as an “insulin sensitizer” via up regulation of its target gene, Genome-2-Bio-Medicine Discovery center (GBMD), 22/September/2014, 09.53 am, http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
